MétaCan
Menu
Back to cohort
Record W3038926436 · doi:10.1001/jamaoncol.2020.2134

Characterization of the Cancer Spectrum in Men With Germline<i>BRCA1</i>and<i>BRCA2</i>Pathogenic Variants

2020· article· en· W3038926436 on OpenAlexafffund
Valentina Silvestri, Goska Leslie, Daniel R. Barnes, Bjarni A. Agnarsson, Kristiina Aittomäki, Elisa Alducci, Irene L. Andrulis, Rósa B. Barkardóttir, Alicia Barroso, Daniel Barrowdale, Javier Benı́tez, Bernardo Bonanni, Åke Borg, Saundra S. Buys, Trinidad Caldés, Maria A. Caligo, Carlo Capalbo, Ian Campbell, Wendy K. Chung, Kathleen Claes, Sarah V. Colonna, Laura Cortesi, Fergus J. Couch, Miguel de la Hoya, Orland Dı́ez, Yuan Chun Ding, Susan M. Domchek, Douglas F. Easton, Bent Ejlertsen, Christoph Engel, D. Gareth Evans, Lídia Feliubadaló, Lenka Foretová, Florentia Fostira, Lajos Géczi, Anne‐Marie Gerdes, Gord Glendon, Andrew K. Godwin, David E. Goldgar, Eric Hahnen, Frans B.L. Hogervorst, John L. Hopper, Peter J. Hulick, Claudine Isaacs, Á. Izquierdo, Paul A. James, Ramūnas Janavičius, Uffe Birk Jensen, Esther M. John, Joseph Vijai, Irene Konstantopoulou, Allison W. Kurian, Ava Kwong, Elisabetta Landucci, Fabienne Lesueur, Jennifer T. Loud, Eva Macháčková, Keivan Majidzadeh‐A, Siranoush Manoukian, Marco Montagna, Lidia Moserle, Anna Marie Mulligan, Katherine L. Nathanson, Heli Nevanlinna, Joanne Ngeow, Liene Ņikitina-Zaķe, Kenneth Offit, Edith Olah, Olufunmilayo I. Olopade, Ana Osório, Laura Papi, Sue K. Park, Inge Søkilde Pedersen, Pedro Pérez‐Segura, Annabeth Høgh Petersen, Pedro Pinto, Berardino Porfirio, Miquel Angel Pujana, Paolo Radice, Johanna Rantala, Muhammad Usman Rashid, Barak Rosenzweig, Maria Rossing, Marta Santamariña, Rita K. Schmutzler, Leigha Senter, Jacques Simard, Christian F. Singer, Ángela R. Solano, Melissa C. Southey, Linda Steele, Zoe Steinsnyder, Dominique Stoppa‐Lyonnet, Yen Y. Tan, Manuel R. Teixeira, Soo‐Hwang Teo, Mary Beth Terry, Mads Thomassen, Amanda E. Toland, Sara Torres‐Esquius, Nadine Tung, Christi J. van Asperen, Ana Vega, Alessandra Viel, Jeroen Vierstraete, Barbara Wappenschmidt, Jeffrey N. Weitzel, Greet Wieme, Sook‐Yee Yoon, Kristin K. Zorn, Lesley McGuffog, Michael T. Parsons, Ute Hamann, Mark H. Greene, Judy A. Kirk, Susan L. Neuhausen, Timothy R. Rebbeck, Marc Tischkowitz, Georgia Chenevix‐Trench, Antonis C. Antoniou, Eitan Friedman, Laura Ottini

Bibliographic record

VenueJAMA Oncology · 2020
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBRCA gene mutations in cancer
Canadian institutionsUniversité LavalUniversity of TorontoUniversity Health NetworkCentre hospitalier universitaire de QuébecLunenfeld-Tanenbaum Research InstituteMount Sinai Hospital
FundersKlinisk Institut, Aalborg UniversitetServicio Gallego de SaludLee Kong Chian School of Medicine, Nanyang Technological UniversityEuropean Regional Development FundMedical Research CouncilCanadian Institutes of Health ResearchManchester Biomedical Research CentreFox Chase Cancer CenterNational Institutes of HealthCentro de Investigación Biomédica en Red de CáncerNational Cancer InstituteLiga Portuguesa Contra o CancroNational Institute of General Medical SciencesInstitut National Du CancerTel Aviv UniversityMinisterio de Economía y CompetitividadLandspítali HáskólasjúkrahúsAalborg UniversitetshospitalFondation ARC pour la Recherche sur le CancerMedizinische Universität WienKarolinska InstitutetHungarian Scientific Research FundGentofte HospitalNederlandse Organisatie voor Wetenschappelijk OnderzoekMinistero della SaluteGeneralitat de CatalunyaAssociazione Italiana per la Ricerca sul CancroAalborg UniversitetDeutsche KrebshilfeNational Breast Cancer FoundationSeoul National UniversityUniversität WienCancer AustraliaNational Institute for Health and Care ResearchGeorgetown UniversityNanyang Technological UniversityCentre Hospitalier Universitaire de QuébecIstituto Oncologico VenetoHelsingin YliopistoUniversité LavalCentres de Recerca de CatalunyaKWF KankerbestrijdingCancer Research UKMemorial Sloan-Kettering Cancer CenterWellcome TrustCollege of Medicine, Seoul National UniversitySusan G. Komen for the CureNational Cancer Centre of SingaporeDeutsches KrebsforschungszentrumUniversità degli Studi di FirenzeInstituto de Investigación Sanitaria de Santiago de CompostelaMinistério da Ciência, Tecnologia e InovaçãoKansas Bioscience AuthorityUniversity of ChicagoCancer Research InstituteDr. Ralph and Marian Falk Medical Research TrustCancer Center, University of KansasCancerfondenFundación Mutua MadrileñaRigshospitaletNational Health and Medical Research CouncilFisher Center for Alzheimer's Research FoundationInstituto de Salud Carlos IIIOhio State UniversityInstitut Català de la SalutUniversity of PennsylvaniaEuropean CommissionBreast Cancer Research Foundation
KeywordsMedicineGermlineCancerBRCA2 ProteinGermline mutationOncologyGeneticsMutationInternal medicineGeneBiology

Abstract

fetched live from OpenAlex

Importance: The limited data on cancer phenotypes in men with germline BRCA1 and BRCA2 pathogenic variants (PVs) have hampered the development of evidence-based recommendations for early cancer detection and risk reduction in this population. Objective: To compare the cancer spectrum and frequencies between male BRCA1 and BRCA2 PV carriers. Design, Setting, and Participants: Retrospective cohort study of 6902 men, including 3651 BRCA1 and 3251 BRCA2 PV carriers, older than 18 years recruited from cancer genetics clinics from 1966 to 2017 by 53 study groups in 33 countries worldwide collaborating through the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Clinical data and pathologic characteristics were collected. Main Outcomes and Measures: BRCA1/2 status was the outcome in a logistic regression, and cancer diagnoses were the independent predictors. All odds ratios (ORs) were adjusted for age, country of origin, and calendar year of the first interview. Results: Among the 6902 men in the study (median [range] age, 51.6 [18-100] years), 1634 cancers were diagnosed in 1376 men (19.9%), the majority (922 of 1,376 [67%]) being BRCA2 PV carriers. Being affected by any cancer was associated with a higher probability of being a BRCA2, rather than a BRCA1, PV carrier (OR, 3.23; 95% CI, 2.81-3.70; P < .001), as well as developing 2 (OR, 7.97; 95% CI, 5.47-11.60; P < .001) and 3 (OR, 19.60; 95% CI, 4.64-82.89; P < .001) primary tumors. A higher frequency of breast (OR, 5.47; 95% CI, 4.06-7.37; P < .001) and prostate (OR, 1.39; 95% CI, 1.09-1.78; P = .008) cancers was associated with a higher probability of being a BRCA2 PV carrier. Among cancers other than breast and prostate, pancreatic cancer was associated with a higher probability (OR, 3.00; 95% CI, 1.55-5.81; P = .001) and colorectal cancer with a lower probability (OR, 0.47; 95% CI, 0.29-0.78; P = .003) of being a BRCA2 PV carrier. Conclusions and Relevance: Significant differences in the cancer spectrum were observed in male BRCA2, compared with BRCA1, PV carriers. These data may inform future recommendations for surveillance of BRCA1/2-associated cancers and guide future prospective studies for estimating cancer risks in men with BRCA1/2 PVs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.475
Threshold uncertainty score0.333

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.257
Teacher spread0.246 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations67
Published2020
Admission routes2
Has abstractyes

Explore more

Same venueJAMA OncologySame topicBRCA gene mutations in cancerFrench-language works237,207